Last Updated: 07 Nov 2024
Executive Summary
DaVita HealthCare Partners Inc. (DVA) is a leading provider of kidney dialysis services in the United States. The company has a market capitalization of $12.06 billion and trades on the NYSE. DVA's latest stock price is $147.07, which is within its 52-week range of $82.79 to $168.5.
Company Overview
DaVita provides a range of dialysis services, including in-center hemodialysis, peritoneal dialysis, and home hemodialysis. The company also offers a variety of other services, such as laboratory testing, pharmacy services, and nutritional counseling. DaVita operates a network of over 2,800 dialysis centers in the United States.
Fundamental Analysis
DVA's financial performance has been strong in recent years. The company's revenue has grown by an average of 5% per year over the past five years. In 2023, DVA reported revenue of $12.67 billion and net income of $941 million. The company's profit margin is 6.53%, and its return on equity is 44.9%.
DVA's balance sheet is also strong. The company has $2.66 billion in cash and equivalents and $3.44 billion in debt. DVA's debt-to-equity ratio is 0.44, which is below the industry average.
Technical Analysis
DVA's stock price has been trending higher in recent months. The stock is currently trading above its 50-day and 200-day moving averages. The stock's relative strength index (RSI) is 58, which indicates that the stock is overbought.
Short Term Outlook
DVA's stock price is likely to continue to trend higher in the short term. The stock is trading above its key moving averages and the RSI is overbought. However, investors should be aware that the stock is overbought and could be due for a pullback.
Long Term Outlook
DVA's long-term outlook is positive. The company is a leader in the kidney dialysis market and is well-positioned to benefit from the growing demand for dialysis services. DVA's strong financial performance and balance sheet also support a positive long-term outlook.
Analyst Recommendations
Analysts are generally positive on DVA's stock. The average analyst rating for DVA is "Hold." However, several analysts have recently upgraded their ratings for the stock. For example, J.P. Morgan upgraded DVA from "Neutral" to "Overweight" in January 2023.
